Royce & Associates LP Has $5.75 Million Stock Holdings in Profound Medical Corp. (NASDAQ:PROF)

Royce & Associates LP lifted its holdings in shares of Profound Medical Corp. (NASDAQ:PROF - Free Report) by 34.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 764,799 shares of the company's stock after acquiring an additional 195,501 shares during the quarter. Royce & Associates LP owned approximately 2.55% of Profound Medical worth $5,746,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Raymond James Trust N.A. raised its holdings in Profound Medical by 14.3% in the 3rd quarter. Raymond James Trust N.A. now owns 12,000 shares of the company's stock valued at $96,000 after acquiring an additional 1,500 shares in the last quarter. MTM Investment Management LLC raised its holdings in Profound Medical by 10.4% in the 4th quarter. MTM Investment Management LLC now owns 18,575 shares of the company's stock valued at $139,000 after acquiring an additional 1,750 shares in the last quarter. Truist Financial Corp acquired a new position in Profound Medical in the 4th quarter valued at $376,000. Vestcor Inc acquired a new position in shares of Profound Medical during the 4th quarter worth $376,000. Finally, K2 Principal Fund L.P. acquired a new position in shares of Profound Medical during the 3rd quarter worth $398,000. 47.86% of the stock is currently owned by institutional investors.

Profound Medical Price Performance

Shares of Profound Medical stock traded down $0.13 during trading on Friday, reaching $6.81. 58,320 shares of the company's stock were exchanged, compared to its average volume of 51,775. The company has a market cap of $204.57 million, a P/E ratio of -5.08 and a beta of 0.78. Profound Medical Corp. has a 1-year low of $5.63 and a 1-year high of $11.42. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.16 and a current ratio of 6.12. The firm's 50-day moving average price is $6.87 and its 200 day moving average price is $7.42.

Remove Ads

Profound Medical (NASDAQ:PROF - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.11. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. As a group, research analysts anticipate that Profound Medical Corp. will post -1.12 earnings per share for the current year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.